# A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

> **NCT03927456** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 357 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** SHR6390
- **DRUG:** Placebo
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT03927456
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-13
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 357 (ESTIMATED)
- **Last updated:** 2021-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03927456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03927456, "A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT03927456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*